Back to Search Start Over

A polymorphism in the 5'-flanking region of the CYP2E1 gene and elevated lung adenocarcinoma risk in a Japanese population

Authors :
Akira Iyoda
Kenzo Hiroshima
Yukiko Haga
Yukio Saitoh
Takehiko Fujisawa
Makoto Suzuki
Masayuki Baba
Fumio Nomura
Takeshi Tomonaga
Toshihiko Iizasa
Hao Chang
Sakae Itoga
Source :
Oncology Reports.
Publication Year :
2005
Publisher :
Spandidos Publications, 2005.

Abstract

Cytochrome P450 2E1 (CYP2E1) catalyzes the metabolic activation of the procarcinogen, N-nitrosodimethylamine, and cytotoxic carbon tetrachloride compounds. A tandem repeat polymorphism in the 5'-flanking region of the CYP2E1 gene was investigated in non-small cell lung carcinoma (NSCLC) patients to clarify the relationship between CYP2E1 gene polymorphism and lung cancer susceptibility. Blood samples were taken from 236 healthy control subjects (192 males and 44 females) and 111 patients (78 males and 33 females) who underwent surgery for NSCLC in Japan. DNA was isolated from these samples and the 5'-flanking region of the CYP2E1 gene was amplified by polymerase chain reaction and examined for tandem repeat polymorphisms using DNA fragment analysis. Sequence analysis confirmed the presence of three alleles, A2, A3, and A4 (361, 367, and 457 bp, respectively), with four genotypes observed in the lung cancer group and five genotypes in the control group. There was a statistically significant difference in genotype distribution between the lung adenocarcinoma and control group (P=0.0088, A4/A4 vs. non-A4/A4). In the lung adenocarcinoma group, the univariate risk estimates for the A4/A4 subgroup compared to the most common subgroup (A2/A2) was 4.300 (95% confidence interval = 1.358-13.618, P=0.0131). We conclude that the A4/A4 genotype of the 5'-flanking region of CYP2E1 was significantly more frequent in lung adenocarcinoma cases than in healthy controls and, therefore, may be involved in the development of lung adenocarcinoma.

Details

ISSN :
17912431 and 1021335X
Database :
OpenAIRE
Journal :
Oncology Reports
Accession number :
edsair.doi.dedup.....517b7dd4faa63ccd3e90d3a90371fc32
Full Text :
https://doi.org/10.3892/or.14.4.919